EE05086B1 - Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus - Google Patents

Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus

Info

Publication number
EE05086B1
EE05086B1 EEP200100252A EEP200100252A EE05086B1 EE 05086 B1 EE05086 B1 EE 05086B1 EE P200100252 A EEP200100252 A EE P200100252A EE P200100252 A EEP200100252 A EE P200100252A EE 05086 B1 EE05086 B1 EE 05086B1
Authority
EE
Estonia
Prior art keywords
primidine
derivatives
preparation
combination
product
Prior art date
Application number
EEP200100252A
Other languages
English (en)
Estonian (et)
Inventor
Adriaan Jan Janssen Paul
Joseph Kukla Michael
De Corte Bart
Ren De Jonge Marc
Heeres Jan
Yung Ho Chih
W. Kavash Robert
Maria Henricus Koymans Lucien
William Ludovici Donald
Jeanne Alfons Van Aken Koen
Jozef Lodewijk Marcel Andries Koenraad
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05086(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200100252A publication Critical patent/EE200100252A/xx
Publication of EE05086B1 publication Critical patent/EE05086B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200100252A 1998-11-10 1999-09-24 Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus EE05086B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines

Publications (2)

Publication Number Publication Date
EE200100252A EE200100252A (et) 2002-10-15
EE05086B1 true EE05086B1 (et) 2008-10-15

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100252A EE05086B1 (et) 1998-11-10 1999-09-24 Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus

Country Status (41)

Country Link
US (5) US6878717B2 (enExample)
EP (2) EP1270560B1 (enExample)
JP (1) JP3635238B2 (enExample)
KR (1) KR100658489B1 (enExample)
CN (1) CN1214013C (enExample)
AP (1) AP1683A (enExample)
AR (1) AR024227A1 (enExample)
AT (2) ATE455107T1 (enExample)
AU (2) AU762523C (enExample)
BG (1) BG65103B1 (enExample)
BR (1) BRPI9915552B8 (enExample)
CA (1) CA2350801C (enExample)
CY (1) CY2008021I2 (enExample)
CZ (1) CZ301367B6 (enExample)
DE (3) DE69941934D1 (enExample)
DK (1) DK1002795T3 (enExample)
EA (1) EA004049B1 (enExample)
EE (1) EE05086B1 (enExample)
ES (2) ES2193664T3 (enExample)
FR (1) FR09C0004I2 (enExample)
HK (1) HK1048817B (enExample)
HR (2) HRP20080359B1 (enExample)
HU (2) HU230394B1 (enExample)
ID (1) ID28376A (enExample)
IL (2) IL143023A0 (enExample)
LT (1) LTC1002795I2 (enExample)
LU (1) LU91528I2 (enExample)
MY (1) MY121108A (enExample)
NL (1) NL300373I2 (enExample)
NO (3) NO318801B1 (enExample)
NZ (1) NZ511116A (enExample)
OA (1) OA11674A (enExample)
PL (1) PL204427B1 (enExample)
PT (1) PT1002795E (enExample)
SI (1) SI1002795T1 (enExample)
SK (2) SK287270B6 (enExample)
TR (1) TR200101306T2 (enExample)
TW (1) TWI238161B (enExample)
UA (1) UA70966C2 (enExample)
WO (1) WO2000027825A1 (enExample)
ZA (1) ZA200103769B (enExample)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28376A (id) * 1998-11-10 2001-05-17 Janssen Pharmaceutica Nv Pirimidina yang menghambat replikasi hiv
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
BRPI0014271B1 (pt) * 1999-09-24 2021-06-22 Janssen Pharmaceutica N.V. Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
US20030004174A9 (en) 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
WO2001085699A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
EP1337931A4 (en) * 2000-11-01 2005-05-11 Snapnames Com Inc DOMAIN NAME ACQUISITION AND MANAGEMENT SYSTEM AND METHOD
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
EP1438053B1 (de) * 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
KR20040048920A (ko) 2001-11-01 2004-06-10 얀센 파마슈티카 엔.브이. 글리코겐 신타아제 키나제 3-베타 저해제(ｇｓｋ저해제)로서의 헤테로아릴 아민
WO2003037869A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2003076401A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
IL164005A0 (en) 2002-03-13 2005-12-18 Janssen Pharmaceutica Nv Carbonylamino-derivatives as novel inhibitiors of histone deacetylase
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
DE60318035T2 (de) * 2002-05-03 2008-12-11 Janssen Pharmaceutica N.V. Polymermikroemulsionen
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
CA2686429C (en) 2002-08-09 2010-11-16 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
BR0316680A (pt) * 2002-11-28 2005-10-18 Schering Ag Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos
PT1599468E (pt) 2003-01-14 2008-01-14 Arena Pharm Inc Derivados de arilo e heteroarilo 1,2,3.-trissubstituídos comomoduladores do metabolismo, e profilaxia e tratamento dedesordens relacionadas tais como diabetes e hiperglicemia
KR101185048B1 (ko) 2003-02-07 2012-09-21 얀센 파마슈티카 엔.브이. Ｈｉｖ 감염 예방용 피리미딘 유도체
CN1747941A (zh) * 2003-02-07 2006-03-15 詹森药业有限公司 抑制hiv的1,2,4－三嗪
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ATE433447T1 (de) 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN1822843B (zh) * 2003-07-17 2010-04-28 泰博特克药品有限公司 制备含有抗病毒药物颗粒的方法
NZ545270A (en) 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2005028479A2 (en) 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives
AU2005218183B2 (en) 2004-03-02 2012-06-07 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
SG156687A1 (en) 2004-07-28 2009-11-26 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006015985A1 (en) 2004-08-10 2006-02-16 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazin-6-one derivatives
ES2371923T3 (es) 2004-09-30 2012-01-11 Tibotec Pharmaceuticals 5-heterociclil-pirimidinas que inhiben el vih.
EP1797047B1 (en) * 2004-09-30 2012-01-25 Tibotec Pharmaceuticals Hiv inhibiting 5-substituted pyrimidines
EP1797048B1 (en) * 2004-09-30 2011-08-17 Tibotec Pharmaceuticals Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
KR20070085286A (ko) * 2004-10-29 2007-08-27 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 바이사이클릭 피리미딘 유도체
US20060106043A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and etravirine
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
EP2388249A1 (en) * 2005-01-27 2011-11-23 Tibotec Pharmaceuticals HIV inhibiting 2-(4-cyanophenylamino) pyrimidine derivatives
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
RU2398768C2 (ru) * 2005-02-18 2010-09-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич производные 2-(4-цианофениламино)-пиримидин-оксида
EP1858861B1 (en) * 2005-03-04 2010-07-07 Tibotec Pharmaceuticals Hiv inhibiting 2-(4-cyanophenyl)-6-hydroxylaminopyrimidines
KR20080015409A (ko) 2005-05-16 2008-02-19 아스트라제네카 아베 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체
RU2458056C2 (ru) 2005-05-26 2012-08-10 Тиботек Фармасьютикалз Лтд Способ получения 4-(1,6-дигидро-6-оксо-2-пиримидинил)амино-бензонитрила
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2628863A1 (en) * 2005-10-06 2007-04-19 University Of Massachusetts Composition and synthesis of new reagents for inhibition of hiv replication
WO2007049041A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
JP5225104B2 (ja) 2006-01-19 2013-07-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 新しい、ヒストンデアセチラーゼのインヒビターとしてのアミノフェニル誘導体
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
DK1981875T3 (da) 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5078986B2 (ja) 2006-03-30 2012-11-21 テイボテク・フアーマシユーチカルズ Ｈｉｖを阻害する５−アミド置換されたピリミジン
JP5070278B2 (ja) 2006-03-30 2012-11-07 テイボテク・フアーマシユーチカルズ Ｈｉｖを阻害する５−（ヒドロキシメチレンおよびアミノメチレン）置換されたピリミジン
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
MX2008015686A (es) * 2006-06-06 2009-01-12 Tibotec Pharm Ltd Procedimiento para preparar formulaciones secadas por aspersion de etravirina.
DK2484346T3 (en) 2006-06-19 2017-04-24 Alpharma Pharmaceuticals Llc Pharmaceutical compositions
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ，インコーポレイテッド 医薬組成物
ES2624593T3 (es) 2006-12-06 2017-07-17 Janssen Sciences Ireland Uc Sal de hidrobromuro de un compuesto anti-VIH.
US9006243B2 (en) 2006-12-29 2015-04-14 Janssen R&D Ireland HIV inhibiting 6-substituted pyrimidines
EA020749B1 (ru) 2006-12-29 2015-01-30 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5,6-замещенные пиримидины
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101955914B1 (ko) 2008-06-27 2019-03-11 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US20100137313A1 (en) * 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
ES2612485T3 (es) 2009-03-30 2017-05-17 Janssen Sciences Ireland Uc Co-cristal de etravirina y nicotinamida
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
BRPI1004934A2 (pt) 2009-06-22 2016-11-29 Emcure Pharmaceuticals Ltd processo para a síntese de inibidor não nucleosídico de transcriptase reversa diarilpirimidínico
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
EP3075730B1 (en) 2010-06-04 2018-10-24 Genentech, Inc. Aminopyrimidine derivatives as lrrk2 modulators
CA2803848A1 (en) 2010-06-28 2012-01-05 Hetero Research Foundation A process for etravirine intermediate and polymorphs of etravirine
JP6068340B2 (ja) 2010-08-10 2017-01-25 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Ｂｔｋ阻害剤のベシル酸塩
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP5957460B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 複素環式化合物またはその使用
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
SG189043A1 (en) 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
WO2012147104A1 (en) 2011-04-26 2012-11-01 Mylan Laboratories Ltd Novel process for the preparation of etravirine
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
JP5993010B2 (ja) 2011-08-23 2016-09-14 エンドゥ ファーマシューティカルズ，インコーポレイティド ピリミド−ピリダジノン化合物及びその使用
US20130123498A1 (en) 2011-10-19 2013-05-16 Maja Sepelj MAJER Process for the preparation of etravirine and intermediates in the synthesis thereof
EP2770830A4 (en) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE)
WO2013109354A2 (en) * 2011-12-07 2013-07-25 Texas Southern University Etravirine formulations and uses thereof
ES2698298T3 (es) 2012-03-15 2019-02-04 Celgene Car Llc Sales de un inhibidor de quinasa receptor de factor de crecimiento epidérmico
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
CA2894466A1 (en) 2012-12-21 2014-06-26 Patrick Colin Uses and methods for the treatment of liver diseases or conditions
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
KR20150119012A (ko) 2013-02-08 2015-10-23 셀진 아빌로믹스 리서치, 인코포레이티드 Erk 억제제 및 이의 용도
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016025561A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Forms and compositions of an erk inhibitor
KR20230151072A (ko) 2015-01-06 2023-10-31 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 상태의 치료 방법
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
CN108349891B (zh) 2015-06-22 2022-04-05 艾尼纳制药公司 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
WO2018201131A1 (en) 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
KR102859841B1 (ko) 2018-06-06 2025-09-12 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4694009A (en) * 1984-06-25 1987-09-15 Ciba-Geigy Corporation Pesticidal compositions
HU206328B (en) 1988-03-31 1992-10-28 Mitsubishi Chem Ind Process for producing 6-substituted pyrimidine derivatives and antiviral phqrmaceutical compositions containing them as active components
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
SI0945443T1 (en) * 1998-03-27 2003-08-31 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
ID28376A (id) * 1998-11-10 2001-05-17 Janssen Pharmaceutica Nv Pirimidina yang menghambat replikasi hiv
WO2001085699A2 (en) * 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Prodrugs of hiv replication inhibiting pyrimidines

Also Published As

Publication number Publication date
SI1002795T1 (en) 2003-10-31
LTPA2008016I1 (lt) 2021-04-26
HUP0104177A3 (en) 2003-01-28
NZ511116A (en) 2003-08-29
CA2350801C (en) 2008-05-20
US20080176880A1 (en) 2008-07-24
NL300373I2 (nl) 2009-04-01
IL169949A (en) 2011-02-28
US8003789B2 (en) 2011-08-23
EA200100536A1 (ru) 2002-02-28
EP1002795B1 (en) 2003-03-05
HRP20080359B1 (hr) 2016-01-01
HU227453B1 (en) 2011-06-28
BG105418A (en) 2001-11-30
JP3635238B2 (ja) 2005-04-06
US20040039005A1 (en) 2004-02-26
ES2338760T3 (es) 2010-05-12
HRP20010161B1 (en) 2009-03-31
AR024227A1 (es) 2002-09-25
NO318801B1 (no) 2005-05-09
KR100658489B1 (ko) 2006-12-18
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
ID28376A (id) 2001-05-17
NO2009003I2 (no) 2010-06-07
ZA200103769B (en) 2002-08-12
EP1270560A1 (en) 2003-01-02
CY2008021I1 (el) 2010-07-28
EE200100252A (et) 2002-10-15
TWI238161B (en) 2005-08-21
HRP20010161A2 (en) 2002-02-28
ATE455107T1 (de) 2010-01-15
DE122009000003I1 (de) 2009-05-20
HRP20010161B9 (hr) 2014-10-24
DE69941934D1 (de) 2010-03-04
ATE233740T1 (de) 2003-03-15
AP1683A (en) 2006-11-29
CA2350801A1 (en) 2000-05-18
JP2002529456A (ja) 2002-09-10
HK1048817A1 (en) 2003-04-17
US20050288278A1 (en) 2005-12-29
AU762523C (en) 2004-02-12
BG65103B1 (bg) 2007-02-28
PL204427B1 (pl) 2010-01-29
WO2000027825A1 (en) 2000-05-18
US7037917B2 (en) 2006-05-02
NO2009003I1 (no) 2009-03-09
BR9915552B1 (pt) 2013-11-19
LU91528I2 (fr) 2009-04-20
OA11674A (en) 2005-01-12
AU2011200708A1 (en) 2011-03-10
CN1214013C (zh) 2005-08-10
NL300373I1 (nl) 2009-03-02
CY2008021I2 (el) 2010-07-28
SK287269B6 (sk) 2010-05-07
ES2193664T3 (es) 2003-11-01
US8530655B2 (en) 2013-09-10
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
NO2021015I1 (no) 2021-03-29
FR09C0004I2 (fr) 2010-06-11
AU6200899A (en) 2000-05-29
AU762523B2 (en) 2003-06-26
HK1025330A1 (en) 2000-11-10
CN1322198A (zh) 2001-11-14
DE69905683T2 (de) 2004-03-18
UA70966C2 (uk) 2004-11-15
CZ301367B6 (cs) 2010-02-03
CZ20011533A3 (cs) 2001-10-17
IL143023A0 (en) 2002-04-21
FR09C0004I1 (enExample) 2009-02-27
EP1002795A1 (en) 2000-05-24
KR20010075235A (ko) 2001-08-09
BR9915552A (pt) 2001-08-14
PL347586A1 (en) 2002-04-08
HK1048817B (en) 2010-04-09
TR200101306T2 (tr) 2001-10-22
MY121108A (en) 2005-12-30
NO20011696D0 (no) 2001-04-04
LTC1002795I2 (lt) 2021-06-10
PT1002795E (pt) 2003-07-31
US6878717B2 (en) 2005-04-12
EA004049B1 (ru) 2003-12-25
SK6032001A3 (en) 2002-01-07
HRP20080359A2 (en) 2008-12-31
US20110263625A1 (en) 2011-10-27
EP1270560B1 (en) 2010-01-13
HUP0104177A2 (hu) 2002-03-28
LU91528I9 (enExample) 2019-01-02
BRPI9915552B8 (pt) 2021-05-25
HU230394B1 (hu) 2016-04-28
NO20011696L (no) 2001-04-04

Similar Documents

Publication Publication Date Title
EE05086B1 (et) Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
EE200000620A (et) 3-(amino- või aminoalküül)püridinooni derivaadid,nende valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE03489B1 (et) Olansapiini polümorfne vorm II, selle saamismeetod ja farmatseutiline preparaat
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
FI950625L (fi) Polysubstituoituja 3-asyyliamino-5-fenyyli-1,4-bentsodiatsepiini-2-onijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04681B1 (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE9800069A (et) Bensotiasolooni derivaadid, protsessid ja kasutatud vaheühendid nende saamiseks ning neid sisaldavad ravimkoostised
EE200100173A (et) 2-fenüülpüraan-4-ooni derivaadid, nende valmistamismeetod ja kasutamine, vaheühendite kasutamine jafarmatseutiline kompositsioon
EE03691B1 (et) 1,2,3,4-tetrahüdrobensofuro[3,4-c]püridiini derivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE04087B1 (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EE9800075A (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine

Legal Events

Date Code Title Description
AA1Y Spc filed

Free format text: PRODUCT NAME: INTELENCE - ETRAVIRINE; REGISTRATION NO/DATE: C(2008)4744 20080828

Spc suppl protection certif: C20080006

Filing date: 20081211

FG1Y Spc granted

Free format text: PRODUCT NAME: INTELENCE - ETRAVIRINE; REGISTRATION NO/DATE: C(2008)4744 20080828

Spc suppl protection certif: C20080006 00021

Filing date: 20081211

Extension date: 20230828

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

SPCZ Extension of supplementary protection certificate: granted [paediatric extension]

Free format text: PRODUCT NAME: ETRAVIRIIN; NATIONAL AUTHORISATION NUMBER: EMA/CHMP/143595/2020; DATE OF AUTHORISATION: 20200326

Spc suppl protection certif: C20080006

Extension date: 20240301